1 / 1

asfotase alfa(Strensiq)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Alexion

Formulation:

INJECTION

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Strensiq(asfotase alfa) Instructions:Uses,Dosage, Side Effects

STRENSIQ (asfotase alfa) is a recombinant human tissue-nonspecific alkaline phosphatase enzyme replacement therapy. It is formulated as a sterile, preservative-free, aqueous solution for subcutaneous injection.

This biologic agent is specifically designed to address the underlying metabolic deficiency in patients with hypophosphatasia (HPP), a rare genetic disorder characterized by defective bone mineralization.

Generic name

asfotase alfa(Strensiq)

English name

asfotase alfa

Alternative Names

Strensiq

Drug prices

Indications

STRENSIQ is indicated for the treatment of patients with perinatal/infantile-onset and juvenile-onset hypophosphatasia (HPP).

Therapeutic Target

Tissue nonspecific alkaline phosphatase (TNSALP)

Active Ingredients

Asfotase alfa

Dosage form

INJECTION

specifications

18mg/0.45mL * 1 Vial/Box

Description

STRENSIQ (asfotase alfa) is a recombinant form of human tissue-nonspecific alkaline- Pharmacokinetic studies show similar results across age groups, like kids under 5 and those 5 to 12.

Dosage and Administration

1. Perinatal/Infantile-Onset HPP:

6 mg/kg/week subcutaneously, either as 2 mg/kg three times per week or 1 mg/kg six times per week.

May be increased to 9 mg/kg/week (3 mg/kg three times per week) if response is inadequate.

2. Juvenile-Onset HPP:

6 mg/kg/week subcutaneously, as 2 mg/kg three times per week or 1 mg/kg six times per week.

CATEGORY NAVIGATION